溴结构域抑制剂十年后：未兑现的承诺？
Bromodomain inhibitors a decade later: a promise unfulfilled?
机构信息
The Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
出版信息
Br J Cancer. 2020 Dec;123(12):1713-1714. doi: 10.1038/s41416-020-01079-x. Epub 2020 Sep 29.
Abstract
Over the last decade, bromodomain inhibitors have emerged as a promising class of anticancer drugs. However, the clinical progress of these agents has faced significant obstacles, which precluded their regulatory approval. This editorial will review the challenges and opportunities associated with the development of bromodomain inhibitors.
摘要
在过去的十年中，溴结构域抑制剂已成为一类很有前途的抗癌药物。然而，这些药物的临床进展面临着重大障碍，这使得它们无法获得监管部门的批准。这篇社论将回顾与溴结构域抑制剂的开发相关的挑战和机遇。
相似文献
1
Bromodomain inhibitors a decade later: a promise unfulfilled?溴结构域抑制剂十年后：未兑现的承诺？
Br J Cancer. 2020 Dec;123(12):1713-1714. doi: 10.1038/s41416-020-01079-x. Epub 2020 Sep 29.
2
Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective.抗癌药物研发中的双激酶-溴结构域抑制剂：结构与药理学视角
J Med Chem. 2016 Oct 27;59(20):9305-9320. doi: 10.1021/acs.jmedchem.6b00438. Epub 2016 Sep 7.
3
Bromodomain inhibitors and cancer therapy: From structures to applications.溴结构域抑制剂与癌症治疗：从结构到应用
Epigenetics. 2017 May 4;12(5):323-339. doi: 10.1080/15592294.2016.1265710. Epub 2016 Dec 2.
4
BET Bromodomain as a Target of Epigenetic Therapy.BET 溴结构域作为表观遗传治疗的靶点
Chem Pharm Bull (Tokyo). 2016;64(6):540-7. doi: 10.1248/cpb.c16-00225.
5
Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors.发挥最佳 BET 作用：BET 抑制剂治疗在恶性肿瘤中的新兴作用。
Pharmacol Ther. 2020 Apr;208:107479. doi: 10.1016/j.pharmthera.2020.107479. Epub 2020 Jan 11.
6
BET Inhibitors as Anticancer Agents: A Patent Review.BET抑制剂作为抗癌药物：专利综述。
Recent Pat Anticancer Drug Discov. 2017 Nov 20;12(4):340-364. doi: 10.2174/1574892812666170808121228.
7
HSP90 inhibitors for cancer therapy and overcoming drug resistance.用于癌症治疗和克服耐药性的热休克蛋白90（HSP90）抑制剂
Adv Pharmacol. 2012;65:471-517. doi: 10.1016/B978-0-12-397927-8.00015-4.
8
Stressing the development of small molecules targeting HSP90.强调开发针对 HSP90 的小分子。
Clin Cancer Res. 2014 Jan 15;20(2):275-7. doi: 10.1158/1078-0432.CCR-13-2571. Epub 2013 Oct 28.
9
Bromodomain inhibitors: what does the future hold?溴结构域抑制剂：未来会怎样？
Clin Adv Hematol Oncol. 2018 Jul;16(7):504-515.
10
BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.BET和EZH2抑制剂：靶向癌症的新方法。
Curr Oncol Rep. 2019 Feb 4;21(2):13. doi: 10.1007/s11912-019-0762-x.
引用本文的文献
1
Topical BET PROTACs for locally restricted protein degradation in the lung.用于肺部局部受限蛋白质降解的局部 BET 蛋白降解靶向嵌合体
RSC Med Chem. 2025 Apr 21. doi: 10.1039/d5md00173k.
2
Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls.肺泡横纹肌肉瘤的分子靶点：进展与陷阱的叙述性综述
Int J Mol Sci. 2025 May 28;26(11):5204. doi: 10.3390/ijms26115204.
3
Clinical approaches to overcome PARP inhibitor resistance.克服聚（ADP - 核糖）聚合酶（PARP）抑制剂耐药性的临床方法。
Mol Cancer. 2025 May 30;24(1):156. doi: 10.1186/s12943-025-02355-1.
4
Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma.新型溴结构域和额外末端结构域抑制剂BI 894999用于晚期实体瘤或弥漫性大B细胞淋巴瘤患者的Ia/Ib期研究的最终结果。
ESMO Open. 2025 Apr 8;10(5):104499. doi: 10.1016/j.esmoop.2025.104499.
5
Epigenetic regulators combined with tumour immunotherapy: current status and perspectives.表观遗传调节剂与肿瘤免疫疗法：现状与展望
Clin Epigenetics. 2025 Mar 21;17(1):51. doi: 10.1186/s13148-025-01856-6.
6
BET degraders reveal BRD4 disruption of 7SK and P-TEFb is critical for effective reactivation of latent HIV in CD4+ T-cells.BET降解剂揭示BRD4对7SK和P-TEFb的破坏对于CD4 + T细胞中潜伏HIV的有效重新激活至关重要。
J Virol. 2025 Apr 15;99(4):e0177724. doi: 10.1128/jvi.01777-24. Epub 2025 Mar 11.
7
YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2 germinal center-derived lymphoma.YPEL2调节BRD4-EZH2双重靶向治疗生发中心来源的EZH2淋巴瘤的疗效。
Neoplasia. 2025 Mar;61:101131. doi: 10.1016/j.neo.2025.101131. Epub 2025 Feb 5.
8
BRD9 promotes the progression of gallbladder cancer via CST1 upregulation and interaction with FOXP1 through the PI3K/AKT pathway and represents a therapeutic target.BRD9通过上调CST1并通过PI3K/AKT途径与FOXP1相互作用促进胆囊癌进展，是一个治疗靶点。
Gene Ther. 2024 Nov;31(11-12):594-606. doi: 10.1038/s41434-024-00488-4. Epub 2024 Sep 21.
9
Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer.自噬和衰老促进 ER 阳性乳腺癌对雌激素抵抗的发展。
Front Endocrinol (Lausanne). 2024 Mar 18;15:1298423. doi: 10.3389/fendo.2024.1298423. eCollection 2024.
10
PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.PRMT5 抑制在体外对 H3K27M 改变的弥漫性中线胶质瘤显示出疗效，但不能延长体内的生存时间。
Sci Rep. 2024 Jan 3;14(1):328. doi: 10.1038/s41598-023-48652-x.
Zotero 插件